A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

The trial tested amycretin in its injectable form, but Novo Nordisk is also separately developing the drug in pill form. Investors cheered an early trial of the pill early last year that showed weight ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to ...

Investing.com - Copenhagen-listed shares in Novo Nordisk (CSE: NOVOb) surged on Friday after the Danish drugmaker said ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.